|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 125.81 USD | -0.39% |
|
+0.18% | -17.73% |
| May. 22 | Eli Lilly's Alzheimer's treatment approved in Australia | FW |
| May. 19 | HSBC Adjusts Price Target on Biogen to $121 From $118, Maintains Hold Rating | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last hours
Enjoy this offer
* See conditions on site
| Capitalization | 18.43B 16.23B 15.12B 13.62B 25.32B 1,570B 28.39B 176B 68.99B 719B 69.13B 67.71B 2,628B | P/E ratio 2025 * |
11.3x | P/E ratio 2026 * | 9.37x |
|---|---|---|---|---|---|
| Enterprise value | 20.34B 17.9B 16.69B 15.03B 27.94B 1,732B 31.32B 194B 76.13B 794B 76.27B 74.71B 2,900B | EV / Sales 2025 * |
2.2x | EV / Sales 2026 * | 1.92x |
| Free-Float |
85.5% | Yield 2025 * |
-
| Yield 2026 * | - |
More valuation ratios
* Estimated data
More news
Last Transcript: Biogen Inc.
More recommendations
More press releases
More news
| 1 day | -0.39% | ||
| 1 week | +0.18% | ||
| Current month | +3.91% | ||
| 1 month | +6.47% | ||
| 3 months | -10.54% | ||
| 6 months | -20.32% | ||
| Current year | -17.73% |
| 1 week | 123.97 |  | 131.13 |
| 1 month | 115.25 | | 131.13 |
| Current year | 110.04 | | 157.09 |
| 1 year | 110.04 | | 238 |
| 3 years | 110.04 | | 319.76 |
| 5 years | 110.04 | | 468.55 |
| 10 years | 110.04 | | 468.55 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 65 | 2022-11-13 | |
Robin Kramer
DFI | Director of Finance/CFO | 59 | 2025-02-28 |
Jane Grogan
CTO | Chief Tech/Sci/R&D Officer | 58 | 2023-10-01 |
| Director | Title | Age | Since |
|---|---|---|---|
Caroline Dorsa
CHM | Chairman | 65 | 2023-06-25 |
Eric Rowinsky
BRD | Director/Board Member | 68 | 2010-03-22 |
Stephen Sherwin
BRD | Director/Board Member | 76 | 2009-12-31 |
| Name | Weight | AuM | 1st Jan change | |
|---|---|---|---|---|
| 4.3% | 1 M€ | 0.00% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -0.39% | +0.18% | -42.30% | -36.91% | 18.43B | ||
| -0.09% | +1.89% | -12.63% | -9.80% | 77.24B | ||
| -5.93% | +1.60% | +31.95% | +24.05% | 52.91B | ||
| -3.52% | -2.33% | +19.58% | +86.57% | 33.35B | ||
| -0.04% | -.--% | +98.69% | +125.77% | 14.02B | ||
| -0.15% | +1.73% | +73.75% | +604.73% | 12.59B | ||
| -0.41% | +1.48% | +11.83% | -16.47% | 12.44B | ||
| +4.18% | +14.90% | +58.38% | +159.87% | 12.34B | ||
| -0.42% | +1.08% | +4.26% | -44.41% | 12B | ||
| -0.79% | -2.90% | -24.18% | -28.38% | 11.04B | ||
| Average | -0.76% | +1.27% | +21.93% | +86.50% | 25.64B | |
| Weighted average by Cap. | -1.62% | +0.73% | +13.86% | +50.81% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 9.26B 8.15B 7.6B 6.84B 12.72B 788B 14.26B 88.28B 34.66B 361B 34.72B 34.01B 1,320B | 9.12B 8.02B 7.48B 6.73B 12.52B 776B 14.04B 86.9B 34.11B 356B 34.18B 33.48B 1,299B |
| Net income | 1.59B 1.4B 1.3B 1.17B 2.18B 135B 2.45B 15.16B 5.95B 62.05B 5.96B 5.84B 227B | 1.92B 1.69B 1.58B 1.42B 2.64B 164B 2.96B 18.35B 7.2B 75.11B 7.22B 7.07B 274B |
| Net Debt | 1.91B 1.68B 1.56B 1.41B 2.62B 162B 2.94B 18.17B 7.13B 74.37B 7.15B 7B 272B | -888M -782M -729M -656M -1.22B -75.66B -1.37B -8.47B -3.33B -34.67B -3.33B -3.26B -127B |
More financial data
* Estimated data
Employees
7,605
Sector
Pharmaceuticals
Calendar
| Date | Price | Change | Volume |
|---|---|---|---|
| 25-05-23 | 125.81 $ | -0.39% | 837,407 |
| 25-05-22 | 126.30 $ | -0.41% | 937,041 |
| 25-05-21 | 126.82 $ | -2.86% | 1,593,947 |
| 25-05-20 | 130.55 $ | +0.86% | 1,684,915 |
| 25-05-19 | 129.44 $ | +3.07% | 2,387,543 |
Delayed Quote Nasdaq, May 23, 2025 at 04:00 pm EDT
More quotes
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
37
Last Close Price
125.81USD
Average target price
171.95USD
Spread / Average Target
+36.67%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- BIIB Stock
Select your edition
All financial news and data tailored to specific country editions
